BioLargo Awarded Multiple Canadian Research Grants Excitement Builds for Its AOS Filter – Financial Support Expands

SANTA ANA, CA / ACCESSWIRE / JULY 28, 2015 / BioLargo, Inc. (OTCQB: BLGO)
announced today that it had been awarded eight Canadian research grants
from provincial and federal funding agencies thus far. In addition, the
company has more than $1,000,000 in additional grants or financial aid
in various stages of application, refinement and/or approvals. The
projects underway total $168,500 supporting the continued development
and commercial refinement of its AOS Filter at its dedicated research lab located within the University of Alberta research center at Agri-Food Discovery Place. Additional projects will be announced as they come to finalization and are expected in the near future.

Researchers call BioLargo’s AOS Filter results “unprecedented.” The AOS
Filter combines iodine, water filter materials and electrolysis within a
water filter device, generating extremely high oxidation potential in
order to eliminate, soluble organic contaminants like acids, solvents,
sulfurs, oil and gas by-products, and pharmaceutical by-products which
are commonly found in all sorts of contaminated water. It also achieves
extremely high rates of disinfection to eliminate infectious biological
pathogens like Salmonella, Listeria and E.coli.

“We are extremely thankful for the expanding financial support from
various federal, provincial and industry stakeholders. Interest in our
technology is expanding in both Canada and internationally as the word
gets out about its high levels of performance and cost-savings
capabilities. We believe our AOS
Filter is the lowest cost, highest impact clean-water-technology to come
to market in recent history. All of these developments also expand our
access to highly qualified researchers to advance the technical data
and refinement as we prepare for commercialization.” said Dennis
Calvert, BioLargo’s president. He added, “All of our grants are applied for through our Canadian subsidiary BioLargo
Water, Inc., led by Richard Smith Ph.D., and typically support specific
research activities, a particular Ph.D. researcher, university
researcher, or doctorial candidate.
None of the funds support general or administrative expenses unrelated
to our research and development activities.We look forward to
expanding these efforts as we expand our capital resources and begin to
identify strategic partners to help bring the AOS Filter to market.”

About BioLargo, Inc.

BioLargo, Inc. (OTCQB: BLGO)
makes life better by delivering technology-based products that help
solve some of the world’s most important problems that threaten water,
food, agriculture, healthcare and energy. More information can be found about the company and its subsidiaries at www.BioLargo.com. The subsidiary BioLargo Water, Inc. (www.BioLargoWater.com) showcases the Advanced Oxidation Systems, including its AOS
Filter, a product in development specifically designed to eliminate
common, troublesome, and dangerous (toxic) contaminants in water in a
fraction of the time and cost of current technologies, It is the winner
of the Technology Star award by New Technology Magazine for its breakthrough innovation for the oil industry. BioLargo also owns a 50% interest in the Isan
System, which was honored with a “Top 50 Water Company for the
21st Century” award by the Artemis Project. The subsidiary Odor-No-More
Inc., features award-winning products serving the pet, equine, and
consumer markets, including the Nature’s Best Solution(R) and Deodorall(R) brands. (www.OdorNoMore.com). The subsidiary Clyra Medical Technologies, Inc. (www.ClyraMedical.com), focuses on advanced wound care management and is preparing to make FDA 510(k) applications in 2015.

Safe Harbor Statement

The statements contained herein, which are not historical, are
forward-looking statements that are subject to risks and uncertainties
that could cause actual results to differ materially from those
expressed in the forward-looking statements, including, but not limited
to, the risks and uncertainties included in BioLargo’s current and future filings with the Securities and Exchange Commission, including those set forth in BioLargo’s Annual Report on Form 10-K for the year ended December 31, 2014.

Company contact:

Dennis Calvert
President
BioLargo, Inc.
949-643-9540 x1

SOURCE: BioLargo, Inc.

ReleaseID: 430888